One clinical use of VIP follows early diagnosis of dementia. Neuronal loss is rarely sudden; the time from detection of gray matter nuclear atrophy to when overt dementia begins can be long. VIP dosing at 300-600mcg/day, taken over 6-9 months has been shown to be safe and effective. We have shown (unpublished) that the mechanism of VIP CORRECTION OF EARLY DEMENTIA usually stems from CORRECTION OF THE UNREGULATED OVER-EXPRESSION OF COAGULATION GENES using VIP provides clinical benefit seen in a small, but ever-growing number of patients. In younger-aged Alzheimer’s patients, improvement coincides with correction of coagulation genes, which in turn reduces overproduction of coagulation gene products.
If you have factor V Leiden, you inherited either one copy or, rarely, two copies of the defective gene. Inheriting one copy slightly increases your risk of developing blood clots. Inheriting two copies — one from each parent — significantly increases your risk of developing blood clots.
The Alzheimer's disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.
News 
Market Data 
Discover 
